Compagnie Lombard Odier SCmA Sells 8,000 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH)

Compagnie Lombard Odier SCmA decreased its holdings in SOPHiA GENETICS SA (NASDAQ:SOPH) by 49.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 8,055 shares of the company’s stock after selling 8,000 shares during the period. Compagnie Lombard Odier SCmA’s holdings in SOPHiA GENETICS were worth $29,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SOPH. Green Alpha Advisors LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at approximately $79,000. Federated Hermes Inc. raised its stake in SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after acquiring an additional 23,000 shares in the last quarter. Banque Cantonale Vaudoise lifted its holdings in shares of SOPHiA GENETICS by 300.0% during the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after acquiring an additional 9,000 shares during the period. Principal Financial Group Inc. boosted its stake in shares of SOPHiA GENETICS by 35.9% in the 2nd quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company’s stock valued at $6,267,000 after purchasing an additional 361,201 shares in the last quarter. Finally, Akre Capital Management LLC bought a new stake in shares of SOPHiA GENETICS in the 1st quarter worth about $1,418,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Stock Down 3.6 %

NASDAQ:SOPH opened at $3.39 on Tuesday. The company has a quick ratio of 4.17, a current ratio of 4.40 and a debt-to-equity ratio of 0.11. SOPHiA GENETICS SA has a 12-month low of $2.70 and a 12-month high of $7.37. The stock’s fifty day simple moving average is $3.67 and its 200-day simple moving average is $4.40. The firm has a market capitalization of $221.29 million, a P/E ratio of -3.02 and a beta of 1.03.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.05. The company had revenue of $15.81 million during the quarter, compared to analyst estimates of $17.58 million. SOPHiA GENETICS had a negative return on equity of 47.40% and a negative net margin of 102.84%. During the same period in the previous year, the company earned ($0.33) EPS. Equities research analysts expect that SOPHiA GENETICS SA will post -0.95 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on SOPH. Guggenheim assumed coverage on shares of SOPHiA GENETICS in a research report on Thursday, June 27th. They issued a “buy” rating and a $6.00 price target on the stock. Morgan Stanley cut shares of SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $10.00 to $5.00 in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada cut their target price on shares of SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.